v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net loss $ (14,942,129) $ (2,490,522)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization and depreciation 91,586 390,467
Common stock and stock option based compensation for employees, board of directors and vendors 712,486 718,632
Net gain on divestiture of subsidiaries (1,392,434)
Reserve on note received in connection with divestiture of subsidiaries 1,500,000
Gain on office lease termination (34,660)
Acquisition contingent consideration fair value adjustment 16,417 87,492
Goodwill impairment 10,857,600
Gain on sale of business (240,000)
Adjustment to operating lease right-of-use assets and liabilities (8,486) (43,605)
Changes in operating assets and liabilities:    
Accounts receivable 178,350 70,914
Deferred costs 46,842 (434,781)
Prepaid expenses and other current assets (384,687) 198,917
Other assets 5,349
Accounts payable (12,985) (128,862)
Accrued liabilities (42,760) 442,496
Deferred revenue 253,842 994,063
Net cash used in operating activities (3,473,924) (116,534)
Cash flow from investing activities:    
Purchase of leasehold improvements and equipment (17,249) (41,453)
Proceeds from sale of business 200,000
Payment of contingent consideration for acquisition (1,500,000) (1,500,000)
Net cash used in investing activities (1,317,249) (1,541,453)
Cash flows provided by financing activities:    
Notes receivable repayments (issuance) 109,768 (93,600)
Proceeds from securities purchase agreement, net 6,785,552
Proceeds from exercise of warrants 175,760
Net cash provided by financing activities 109,768 6,867,712
Net change in cash and cash equivalents (4,681,405) 5,209,725
Cash and cash equivalents, beginning of period 6,832,725 1,848,295
Cash and cash equivalents, end of period $ 2,151,320 $ 7,058,020